Jaguar Animal Health Inc (NASDAQ:JAGX) was the recipient of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 1,413,939 shares, a growth of 57.6% from the February 28th total of 897,371 shares. Currently, 15.2% of the company’s stock are short sold. Based on an average daily trading volume, of 796,581 shares, the days-to-cover ratio is presently 1.8 days.
A hedge fund recently raised its stake in Jaguar Animal Health stock. Kingdon Capital Management L.L.C. increased its position in shares of Jaguar Animal Health Inc (NASDAQ:JAGX) by 28.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,297,815 shares of the company’s stock after buying an additional 289,173 shares during the period. Kingdon Capital Management L.L.C. owned 10.52% of Jaguar Animal Health worth $917,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 22.46% of the company’s stock.
Separately, Zacks Investment Research raised Jaguar Animal Health from a “sell” rating to a “hold” rating in a report on Tuesday, January 10th.
Jaguar Animal Health (NASDAQ:JAGX) opened at 0.99 on Tuesday. The company has a 50-day moving average price of $1.03 and a 200 day moving average price of $0.90. Jaguar Animal Health has a 12-month low of $0.50 and a 12-month high of $3.79. The stock’s market cap is $13.87 million.
COPYRIGHT VIOLATION WARNING: This piece was published by Mideast Time and is the sole property of of Mideast Time. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.mideasttime.com/jaguar-animal-health-inc-jagx-short-interest-up-57-6-in-march/1589767.html.
About Jaguar Animal Health
Jaguar Animal Health, Inc is an animal health company. It is focused on developing and commercializing gastrointestinal products for companion and production animals, foals, and horses. Canalevia is its prescription drug product candidate, intended for treatment of various forms of diarrhea in dogs. Canalevia is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient (API) isolated and purified from the Croton lechleri tree.
Receive News & Ratings for Jaguar Animal Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health Inc and related companies with MarketBeat.com's FREE daily email newsletter.